Pfizer Sickle Cell Engagement Survey
Help shape the future of future programs to help meet your needs effectively. At Pfizer, we believe that truly supporting people with sickle cell disease means seeing and understanding each unique journey. By taking this survey, you help us continue to improve as we show up, listen, and create meaningful change—because you are more than your condition.

What is Sickle Cell Disease?
Sickle Cell Disease is an inherited red blood cell disorder that causes healthy, round red blood cells to become hard, sticky, and c-shaped—just like the farm tool called a “sickle”.
Live Your Best Life
with Sickle Cell Disease
Latest News
- MARAC Statement: Pfizer Inclacumab Announcementby Emma Day on August 15, 2025 at 3:45 pm
August 15, 2025 – In a statement issued today, Pfizer announced the results of their Phase 3 THRIVE-131 study evaluating inclacumab. Although inclacumab was generally well tolerated in THRIVE-131, the study results concluded that inclacumab “did not meet its primary endpoint of significant reduction in the rate of vaso-occlusive crises (VOCs) in participants receiving inclacumab The post MARAC Statement: Pfizer Inclacumab Announcement appeared first on Sickle Cell Disease Association of America Inc..
